1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Glioblastoma Multiforme Market
2.2. Global Glioblastoma Multiforme Market, By Drug Type, 2023 (US$ Million)
2.3. Global Glioblastoma Multiforme Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Glioblastoma Multiforme Market: Competitive Analysis
3.1. Market Positioning of Key Glioblastoma Multiforme Market Vendors
3.2. Strategies Adopted by Glioblastoma Multiforme Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Glioblastoma Multiforme Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Glioblastoma Multiforme Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Temozolomide
5.3.2. Bevacizumab
5.3.3. Carmustine


6. North America Glioblastoma Multiforme Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
6.3.Glioblastoma Multiforme Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)

7. UK and European Union Glioblastoma Multiforme Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
7.3.Glioblastoma Multiforme Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)

8. Asia Pacific Glioblastoma Multiforme Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
8.3.Glioblastoma Multiforme Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)

9. Latin America Glioblastoma Multiforme Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
9.3.Glioblastoma Multiforme Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)

10. Middle East and Africa Glioblastoma Multiforme Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
10.3.Glioblastoma Multiforme Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Glioblastoma Multiforme Market: By Drug Type, 2022-2032, USD (Million)

11. Company Profile
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Activartis GmbH
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Agenus Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Arog Pharmaceuticals, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Bristol-Myers Squibb Company
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Cavion LLC
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Celldex Therapeutics, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Cortice Biosciences Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Eisai Co., Ltd.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. F. Hoffmann-La Roche Ltd.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Exelixis Inc.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Peregrine Pharmaceuticals, Inc.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives